Hyper-IgE Syndrome (Job Syndrome)
A rare primary immunodeficiency marked by extremely high IgE levels, recurrent skin and lung infections, eczema, and distinctive facial and skeletal features.
- Rare primary immunodeficiency
- Recurrent skin and lung infections
- Genetic testing available
- Multidisciplinary management
- Estimated Prevalence
- Very Rare (<300 reported families)
- Main Genetic Cause
- STAT3 or DOCK8 Mutation
- Typical Onset
- Infancy
- Advanced Therapies
- Targeted Immune Support
What Is Hyper-IgE Syndrome?
Hyper-IgE Syndrome (HIES), also known as Job Syndrome, is a rare primary immunodeficiency characterized by markedly elevated serum IgE levels, recurrent skin and lung infections (often with Staphylococcus aureus), chronic eczema, and in the autosomal dominant form, distinctive facial features and connective tissue abnormalities. It results from mutations affecting immune signaling pathways, most commonly STAT3.
Types of Hyper-IgE Syndrome
HIES is broadly divided based on the underlying gene and inheritance pattern, which significantly affects clinical course and complications.
Symptoms of Hyper-IgE Syndrome
Symptoms usually begin in infancy and involve the skin, lungs, and, in STAT3 disease, the skeleton and connective tissue.
Causes and Risk Factors
HIES is caused by inherited mutations affecting genes involved in immune cell signaling and differentiation.
How Hyper-IgE Syndrome Is Diagnosed
Diagnosis combines clinical scoring of characteristic features with laboratory and genetic testing.
Disease Severity Classification
HIES is not staged like cancer, but severity is generally assessed by infection burden, organ involvement, and cumulative lung damage.
Standard Treatment Approach
Management focuses on preventing and treating infections, supporting skin barrier health, and monitoring for organ complications.
Advanced and Emerging Therapies
For severe DOCK8 deficiency, curative options exist, while STAT3 disease management increasingly involves targeted immune support.
Hematopoietic Stem Cell Transplant
Allogeneic HSCT for DOCK8 Deficiency
Can be curative for autosomal recessive DOCK8 deficiency when performed early, particularly with a matched donor.
Immunoglobulin Replacement
IVIG / SCIG Support
Used selectively to support antibody function in patients with additional antibody deficiency.
Targeted Cytokine-Pathway Therapy
Investigational JAK/STAT-Pathway Modulators
Being explored for STAT3-related immune dysregulation features.
Gene Therapy Research
Experimental Gene Correction Approaches
Early-stage research for DOCK8 deficiency aiming to avoid the risks of transplant.
Key Biomarkers and Laboratory Markers
Specific laboratory findings support diagnosis and ongoing monitoring of HIES.
When to Seek a Second Opinion
Given the rarity and complexity of HIES, specialist input can be valuable at key decision points.
Clinical Trials and Research
Outlook and Long-Term Prognosis
Prognosis varies by subtype: many people with STAT3 HIES live into adulthood with appropriate infection prevention, while DOCK8 deficiency carries a more guarded course without transplant.
Supportive and Quality-of-Life Care
Beyond infection management, supportive care addresses skin comfort, dental and skeletal health, and psychosocial wellbeing.
How CancerFax Helps You Explore Treatment Options
CancerFax can help you compile your immunology records and connect with specialists experienced in managing Hyper-IgE Syndrome, including transplant evaluation where relevant.
Get a free case reviewFrequently Asked Questions About Hyper-IgE Syndrome
Hyper-IgE Syndrome is a rare genetic primary immunodeficiency causing very high IgE levels, recurrent skin and lung infections, eczema, and, in some forms, distinctive skeletal and facial features.
The name references the biblical figure Job, who suffered recurrent boils, reflecting the recurrent skin abscesses seen in this condition.
STAT3 deficiency (autosomal dominant) typically involves skeletal, dental, and vascular features alongside infections, while DOCK8 deficiency (autosomal recessive) tends to involve more severe combined immune problems, viral skin infections, and allergies, without the skeletal features.
Diagnosis combines clinical scoring of infection history and physical features with blood testing for elevated IgE and eosinophils, confirmed by genetic testing for STAT3 or DOCK8 mutations.
STAT3 HIES is generally managed long-term with infection prevention rather than cured, while DOCK8 deficiency can potentially be cured with hematopoietic stem cell transplant.
Recurrent skin abscesses, often caused by Staphylococcus aureus, and pneumonia are most common, with DOCK8 deficiency also associated with severe viral skin infections.
Yes. STAT3 HIES is typically autosomal dominant, while DOCK8 deficiency is autosomal recessive, meaning both parents carry a copy of the mutated gene.
Eczema in HIES can be more severe and persistent than typical eczema and often needs intensive, ongoing skin care alongside infection prevention.
Yes, particularly with DOCK8 deficiency, which carries an increased risk of lymphoma and other malignancies, making regular monitoring important.
Yes. CancerFax can help you organize and send your medical reports for specialist review, coordinate a second opinion, and explore access to advanced therapies such as stem cell transplant, including international coordination where relevant.
Need Help Navigating Hyper-IgE Syndrome Care?
Send your medical reports for review and let our team help you connect with specialists and explore advanced treatment options.